1. Signaling Pathways
  2. GPCR/G Protein
  3. GLP Receptor

GLP Receptor

GLP Receptor

The GLP receptors contain two family members, GLP-1 receptor (GLP1R, or GLP-1R) and GLP-2 receptor (GLP2R or GLP-1R), activated by the glucagon-like peptides (GLPs). GLPs are s secreted by intestinal cells; causes insulin release; inhibits glucagon secretion, appetite, and energy intake; and delays gastric emptying because GLP receptors are located on the gut, pancreas, brainstem, hypothalamus, and vagal-afferent nerves. GLP-1 has only one known receptor, GLP1R, and regulates gut motility, appetite, islet function, and glucose homeostasis, whereas GLP-2, the agonist of GLP2R, enhances intestinal nutrient absorption. GLP-1R agonists are used to treat diabetes and obesity, and a GLP-2R agonist is approved to treat short bowel syndrome. An investigation of the actions of GLP receptor activation on gallbladder motility has demonstrated that GLP-2 receptor activation increases gallbladder volume in vivo and decreases spontaneous activity in GBSM bundles ex vivo. Like the inhibitory transmitters, which elicit their actions via an adenylate cyclase-protein kinase A-KATP channel pathway, the GLP-2 receptor signals through this same pathway.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P4386
    (Asp28)-Exenatide
    Agonist
    (Asp28)-Exenatide is a degradation product of exenatide (HY-13443). (Asp28)-Exenatide can be used as a GLP-1R agonist.
    (Asp28)-Exenatide
  • HY-P10031
    SAR441255
    Agonist
    SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys.
    SAR441255
  • HY-153193
    LSN3160440
    Modulator
    LSN3160440 is an allosteric modulator of GLP-1R, which acts as a protein–protein interaction (PPI) stabilizer or molecular glue to assist in the adhesion of inactive GLP-1 (9-36) NH2 on GLP-1R.
    LSN3160440
  • HY-162434
    I-128
    Agonist
    I-128 is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0122 nM.
    I-128
  • HY-163996
    DD202-114
    Agonist 98.47%
    DD202-114 is a potent and selective GLP1R agonist. DD202-114 promots cAMP accumulation. DD202-114 reduces blood glucose levels and food intake. DD202-114 has the potential for the research of type 2 diabetes (T2DM) and obesity.
    DD202-114
  • HY-161915
    GLP-1R agonist 23
    Agonist
    GLP-1R agonist 23 (Example 376) is a GLP-1R agonist with an EC50 of 0.056 nM. GLP-1R agonist 23 can be used in diabetes research.
    GLP-1R agonist 23
  • HY-147626
    GLP-1R agonist 13
    Agonist
    GLP-1R agonist 13 (Compound 24) is a GLP-1 receptor agonist.
    GLP-1R agonist 13
  • HY-139276
    Pal-Glu(OSu)-OH
    ≥98.0%
    Pal-Glu(OSu)-OH is a side chain of Liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used for type 2 diabetes mellitus research.
    Pal-Glu(OSu)-OH
  • HY-P10271
    RG7697
    Agonist
    RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property.
    RG7697
  • HY-P5311
    Albiglutide
    Agonist
    Albiglutide is a long acting GLP-1 receptor agonist. Albiglutide can be used for research of Type 2 diabetes.
    Albiglutide
  • HY-P10312
    SPN009
    Agonist
    SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC50 of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models.
    SPN009
  • HY-162979
    GLP-1R agonist 25
    Agonist
    GLP-1R agonist 25 (compound 13) is a GLP1-R agonist, with an EC50 of 0.167 nM. GLP-1R agonist 25 can be used in type II diabetes research.
    GLP-1R agonist 25
  • HY-P10337
    OXM-7
    Agonist
    OXM-7 is a dual agonist of GLP-1R (EC50=0.024 nM) and GCGR (EC50=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism.
    OXM-7
  • HY-P4841
    GLP-1 (7-36)-Lys(biotinyl) amide (human, bovine, guinea pig, mouse, rat)
    GLP-1 (7-36)-Lys(biotinyl) amide (human, bovine, guinea pig, mouse, rat) is a biotinylated GLP-1 fragment, corresponding to the 7-36 sequence of GLP-1.
    GLP-1 (7-36)-Lys(biotinyl) amide (human, bovine, guinea pig, mouse, rat)
  • HY-W823500
    GLP-1 Receptor modulator 1
    GLP-1 Receptor modulator 1 (Compound 7) is a potent GLP-1 receptor positive allosteric modulator. GLP-1 Receptor modulator 1 can be used for the research of obesity and type 2 diabetes.
    GLP-1 Receptor modulator 1
  • HY-168585
    GLP-1R agonist 26
    Agonist
    GLP-1R agonist 26 (compound 1) is a glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC50 of <10 nM.
    GLP-1R agonist 26
  • HY-164535
    Maridebart cafraglutide
    Agonist
    Maridebart cafraglutide (AMG 133) is an antibody-peptide conjugate acting as a GLP-1 receptor agonist and an antagonist of the GIP receptor. Maridebart cafraglutide reduces body weight and improve metabolic markers in male obese mice and cynomolgus monkeys. Maridebart cafraglutide is promising for research of obesity.
    Maridebart cafraglutide
  • HY-164774
    (4S)-GLP-1 receptor agonist 14
    Modulator
    (4S)-GLP-1 receptor agonist 14 (Compound 73) is a GLP-1 receptor modulator.
    (4S)-GLP-1 receptor agonist 14
Cat. No. Product Name / Synonyms Application Reactivity